RadNetRDNT
RDNT
About: RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
Employees: 11,021
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
157% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 21
8% more funds holding
Funds holding: 298 [Q3] → 323 (+25) [Q4]
1.54% more ownership
Funds ownership: 84.72% [Q3] → 86.26% (+1.54%) [Q4]
5% more call options, than puts
Call options by funds: $7.22M | Put options by funds: $6.9M
3% more capital invested
Capital invested by funds: $4.35B [Q3] → $4.46B (+$112M) [Q4]
4% less repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 116
18% less funds holding in top 10
Funds holding in top 10: 11 [Q3] → 9 (-2) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$60
15%
upside
Avg. target
$66
27%
upside
High target
$74
41%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Truist Securities David Macdonald 54% 1-year accuracy 55 / 101 met price target | 41%upside $74 | Buy Maintained | 11 Apr 2025 |
Barclays Andrew Mok 37% 1-year accuracy 22 / 60 met price target | 15%upside $60 | Overweight Maintained | 24 Mar 2025 |
Raymond James John Ransom 22% 1-year accuracy 2 / 9 met price target | 24%upside $65 | Strong Buy Upgraded | 5 Mar 2025 |
Financial journalist opinion
Based on 4 articles about RDNT published over the past 30 days
Positive
Seeking Alpha
1 day ago
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Neutral
GlobeNewsWire
6 days ago
RadNet, Inc. Announces Date of its First Quarter 2025 Financial Results Conference Call
LOS ANGELES, April 24, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its first quarter 2025 financial results on Monday, May 12, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
Neutral
Business Wire
1 week ago
ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of iCAD, Inc. (NasdaqCM: ICAD) to RadNet, Inc. (NasdaqGM: RDNT). Under the terms of the proposed transaction, shareholders of iCAD will receive 0.0677 shares of RadNet for each share of iCAD that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequat.
Neutral
GlobeNewsWire
2 weeks ago
RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer
LOS ANGELES and NASHUA, N.H., April 15, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, and iCAD, Inc. (NASDAQ: ICAD) (“iCAD”), a global leader in providing clinically proven AI-powered breast health solutions, announced today that they have entered into a definitive merger agreement under which RadNet will acquire iCAD in an all stock transaction.
Positive
Benzinga
1 month ago
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Neutral
GlobeNewsWire
1 month ago
RadNet, Inc. to Present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference March 17th, 2025
LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Executive Officer, will be presenting virtually at the 35th Oppenheimer Healthcare MedTech & Services Conference on Monday, March 17, 2025 at 12:40 p.m. Eastern Time.
Neutral
Seeking Alpha
2 months ago
RadNet, Inc. (RDNT) Q4 2024 Earnings Call Transcript
RadNet, Inc. (NASDAQ:RDNT ) Q4 2024 Earnings Conference Call February 28, 2025 10:30 AM ET Company Participants Mark Stolper - Executive Vice President & Chief Financial Officer Howard Berger - President & Chief Executive Officer Conference Call Participants David MacDonald - Truist Brian Tanquilut - Jefferies John Ransom - Raymond James Andrew Mok - Barclays Larry Solow - CJS Securities Jim Sidoti - Sidoti & Company Operator Good day, and welcome to the RadNet, Inc. Fourth Quarter 2024 Financial Results Conference Call. All participants will be in a listen-only mode.
Positive
Zacks Investment Research
2 months ago
RadNet (RDNT) Tops Q4 Earnings and Revenue Estimates
RadNet (RDNT) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.20 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
RadNet Reports Fourth Quarter 2024 Results, Including Record Revenue and Adjusted EBITDA(1) and Releases 2025 Financial Guidance
LOS ANGELES, Feb. 27, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 398 owned and/or operated outpatient imaging centers, today reported financial results for its fourth quarter and full-year ended December 31, 2024.
Neutral
GlobeNewsWire
2 months ago
RadNet and OB/GYN Specialists of the Palm Beaches Enhance Breast Cancer Screening with State-of-the-Art Imaging Services
South Florida's largest OB/GYN provider innovates with AI-powered breast screening. South Florida's largest OB/GYN provider innovates with AI-powered breast screening.
Charts implemented using Lightweight Charts™